Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2021-09-30 Director's Dealing
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-09-30 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-09-28 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a distribution agreement for an at-the-market offering of common stock. It includes details about the agreement, commission, indemnification, and intended use of proceeds. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is an announcement of a capital raising agreement and related financing activity. Therefore, it fits best under the category Capital/Financing Update (CAP). The document length is over 6,000 characters, so it is not a mere announcement of a report publication. Hence, the classification is CAP with high confidence.
2021-09-03 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement on Form S-3. It details an offering of common stock up to $50 million, including terms of the distribution agreement with Raymond James, compensation, risk factors, use of proceeds, and other offering details. This type of document is a capital raising disclosure, specifically a prospectus supplement for a securities offering. It is not an annual report, earnings release, management discussion, or any other report type. It is a detailed disclosure related to financing activities and capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement or regulatory filing but a substantive offering document.
2021-09-03 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-08-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 17, 2021. It announces the termination of a material definitive agreement (the Open Market Sale Agreement) between ADMA Biologics, Inc. and Jefferies LLC. The content focuses on the termination notice and related procedural details, with no financial statements or detailed financial data included. The document is relatively short (3785 characters) and serves as a regulatory announcement of a corporate event rather than a full financial report or detailed management discussion. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2021-08-17 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.